ClinicalTrials.gg
Not yet recruitingNCT07011095SWITCH-AFUpdated Jun 8, 2025

DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial

An Early Phase 1 interventional study of VKA and Direct Oral Anticoagulant (DOAC) in Atrial Fibrillation (AF) and Stroke (in Patients With Atrial Fibrillation), sponsored by Population Health Research Institute. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-08.

Sponsored by Population Health Research Institute · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Atrial Fibrillation by Population Health Research Institute — 6 open to participants now, 6 under way, 1 of them phase 3. Atrial Fibrillation · Population Health Research Institute.

Planned enrollment
16th of 24
100 · median 300
Started
2025
the only one that year
Phase 1
Only one
of the 30
Registered
30th of 30
by date

Among the 30 studies in Atrial Fibrillation by Population Health Research Institute, this one is the 16th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2025, is the only one in phase 1, and was the 30th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

6 of the 30 studies in Atrial Fibrillation by Population Health Research Institute are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Atrial Fibrillation by Population Health Research Institute, or all of them as a file.
02

Study summary

People with atrial fibrillation who have a stroke while receiving a DOAC are at increased risk of experiencing another stroke. Physicians do not know the best medication to prevent another stroke in this group of people. Options include continuing the same DOAC, switching to another DOAC or switching to warfarin.

The investigators of the SWITCH-AF trial are trying to find out whether switching to warfarin or continuing a DOAC is better for preventing stroke.

The purpose of this study, called a pilot study, is to test the study plan and to find out whether enough participants will join a larger study that answers the question. A pilot study involves a small number of participants and it is not expected to tell us which treatment is better.

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Stroke (in Patients With Atrial Fibrillation)

Keywords

  • stroke
  • atrial fibrillation
  • A-Fib
  • SWITCH-AF
  • DOAC
  • Warfarin
  • Anticoagulant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written provided.
  2. Age >18 years.
  3. Documented history of AF or atrial flutter.
  4. Ischemic stroke while on a DOAC within 14 days prior to enrollment identified on imaging.
  5. In the opinion of the investigator, it is safe to initiate oral anticoagulation with either a VKA or a DOAC within 24 hours of randomization-

Exclusion criteria

Exclusion Criteria:

  1. There is strong evidence for the qualifying stroke event to be associated with permanent discontinuation of DOAC therapy (for any reason)
  2. Patient is unable or unwilling to take oral anticoagulation
  3. History of intracranial bleeding.
  4. Patient is on chronic hemodialysis or likely to need renal replacement therapy during the course of the trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    VKA Arm

    Vitamin K Antagonist

    Drug: VKA

  • Experimental
    DOAC Arm

    Direct oral anticoagulant (locally approved)

    Drug: Direct Oral Anticoagulant (DOAC)

Interventions

06

What researchers measure

Primary outcomes

  1. Feasibility - Recruitment

    Recruitment rate; 1 patient per month per center at 9 Canadian stroke centers

    Time frame: From site activation until the end of recruitment (approximately 24 months)

Secondary outcomes

  1. Feasibility - Adherence to Assigned Medication

    Proportion of participants who cross-over (i.e., vitamin K antagonist to DOAC, or DOAC to vitamin K antagonist) is \<5%

    Time frame: Enrollment to final visit (average 12 months)

  2. Feasibility - Retention

    Retention of ≥95% of study participants

    Time frame: At 6 months from randomization

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Feb 2027, 17 months later.

Of 20 phase 1 interventional studies under Atrial Fibrillation, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 17 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 8, 2025
StartEst.
Sep 3, 2025
Primary completionEst.
Feb 3, 2027
CompletionEst.
Jun 3, 2027
Last update
Jun 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07011095
Responsible party
Sponsor
First posted
Jun 8, 2025
Start date
Sep 3, 2025 (estimated)
Primary completion
Feb 3, 2027 (estimated)
Completion
Jun 3, 2027 (estimated)
Last update
Jun 8, 2025

Study contacts

Jodi Miller, Ph.D
Contact
switch-af@phri.ca
905-521-2100
Amanda Taylor, BSc.
Contact
switch-af@phri.ca
905-521-2100

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Direct Oral Anticoagulant

Start the discussion